# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
ULBI: 26% | Ultralife shares are trading higher after the company reported better-than-expected Q1 financial results.CDTX: 41% ...
In addition, the Company announced preliminary XHANCE net product revenue of $14.9 million for the three months ended March 31,...
Lake Street analyst Thomas Flaten maintains OptiNose (NASDAQ:OPTN) with a Buy and raises the price target from $3 to $4.
HC Wainwright & Co. analyst Matthew Caufield reiterates OptiNose (NASDAQ:OPTN) with a Buy and maintains $5 price target.